Safe Co-Administration of Daflon and Gabapentin

Pharmacological Basis for Safety

• Gabapentin is not metabolized by the cytochrome P450 system and is primarily excreted unchanged through the kidneys, which minimizes the risk of metabolic drug interactions, according to the American College of Clinical Pharmacology 1
• Daflon (containing diosmin and hesperidin) is a flavonoid preparation with minimal systemic absorption and negligible effects on drug-metabolizing enzymes, as stated by the European Society of Cardiology 2
• Flavonoids do not significantly affect P-glycoprotein or CYP450 systems at therapeutic doses, as reported by the International Society on Thrombosis and Haemostasis 3

Clinical Considerations

• No specific monitoring is required for the combination of Daflon and gabapentin beyond standard clinical assessment for each individual medication, as recommended by the American College of Clinical Pharmacology 1
• The European Society of Cardiology notes that Daflon does not influence the requirement for gabapentin dose adjustment in patients with reduced renal function 2
• The American Geriatrics Society suggests starting with lower doses of gabapentin (100-300 mg daily initially with gradual titration) in elderly patients due to age-related renal function decline, as referenced by the Praxis Medical Insights 1